Start Date
March 31, 2012
Primary Completion Date
March 31, 2014
Study Completion Date
August 31, 2014
Pegylated Interferon Lambda
Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
Pegylated Interferon Alfa-2a
Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
Ribavirin
Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
Local Institution, Hong Kong
Local Institution, Taipei
Local Institution, Taipei
Local Institution, Taichung
Local Institution, Tainan City
Local Institution, Kaohsiung City
Local Institution, Budapest
Local Institution, Budapest
Local Institution, Leiden
Local Institution, Miskolc
Local Institution, Debrecen
Local Institution, Cairo
Local Institution, Rochester
Local Institution, A Coruña
Local Institution, Diyarbakır
Local Institution, Madrid
Local Institution, Istanbul
Local Institution, Bornova Izmir
Local Institution, Shebin Elkom
Local Institution, Trabzon
Local Institution, Houston
Local Institution, Kaohsiung City
Local Institution, San Diego
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Moscow
Local Institution, Singapore
Local Institution, Gūrgaon
Local Institution, Ludhiana
Local Institution, Poselok Noviy
Local Institution, Singapore
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Saint Petersburg
Local Institution, Smolensk
Local Institution, Smolensk
Local Institution, Kaluga
Local Institution, Timișoara
Local Institution, Singapore
Local Institution, Lipetsk
Local Institution, Volgograd
Local Institution, Saratov
Local Institution, Yoshkar-Ola
Local Institution, Nagpur
Local Institution, Samara
Local Institution, Tolyatti
Local Institution, Hyderabad
Local Institution, Singapore
Local Institution, Nizhny Novgorod
Local Institution, Coimbatore
Local Institution, Iași
Local Institution, Vancouver
Local Institution, Vaughan
Local Institution, Bogotá
Local Institution, Medellín
Local Institution, Santiago de Cali
Local Institution, Lai Chi Kok
Local Institution, Tai Po
Local Institution, Dublin
Local Institution, Hradec Králové
Local Institution, Prague
Local Institution, Ústí nad Labem
Local Institution, New Delhi
Local Institution, Dublin
Local Institution, Amsterdam
Local Institution, Bialystok
Local Institution, Bydgoszcz
Local Institution, Chorzów
Local Institution, Czeladź
Local Institution, Kielce
Local Institution, Krakow
Local Institution, Lodz
Local Institution, Lublin
Local Institution, Olsztyn
Local Institution, Puławy
Local Institution, Racibórz
Local Institution, Sosnowiec
Local Institution, Warsaw
Local Institution, Wroclaw
Local Institution, Zielona Góra
Local Institution, Bucharest
Local Institution, Busan
Local Institution, Busan
Local Institution, Daegu
Local Institution, Incheon
Local Institution, Incheon
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Suwon
Local Institution, Barcelona
Local Institution, Barcelona
Local Institution, Barcelona
Local Institution, Ankara
Local Institution, London
Local Institution, Edinburgh
Local Institution, Birmingham
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY